Companies / PODD vs BSX
PODD vs BSX: Insulet and Boston Scientific
Insulet (PODD) reported $2.7B in revenue against a 9.1% net margin, while Boston Scientific (BSX) reported $20.1B at a 14.4% net margin, most recently.
| Metric | PODD | BSX |
|---|---|---|
| Revenue | $2.7B | $20.1B |
| Net Income | $0.2B | $2.9B |
| Gross Margin | 71.6% | 69.0% |
| Operating Margin | 17.5% | 18.0% |
| EPS (Diluted) | $3.48 | $1.94 |
| Free Cash Flow | $0.4B | $3.7B |
| Total Debt | $0.9B | $11.4B |
| P/E Ratio | 81.7× | 49.2× |
| P/B Ratio | 13.2× | n/m |
| Stock Price | $153.92 | $44.62 |
Free: last 5 years
| Fiscal year | FY2009 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PODD Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $1.1B | $1.3B | $1.7B | $2.1B | $2.7B |
| BSX Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B |